Origenis Broadens Research Alliance with Alcon
to Develop Novel Ophthalmic Compounds

Munich, Germany, October 23, 2008 - Origenis GmbH today announced that it broadened its drug discovery research alliance with Alcon Research, Ltd. (ARL) to create and develop small molecule drugs for important ophthalmic targets. ARL is an affiliate of Alcon, Inc. (NYSE:ACL), the world’s largest eye care company. The alliance combines Origenis' capabilities in compound design, chemical synthesis, and screening with Alcon's applied biology, pharmacology, and development expertise in ophthalmology.

Alcon Announces Two Agreements Designed to
Expand Future Drug Portfolio

Alcon has executed a new agreement and broadened an existing agreement with two different companies to expand its products under development. Alcon entered into a licensing agreement with GlaxoSmithKline for global ophthalmic rights to cilomilast, a phosphodiesterase IV inhibitor. In addition to this new agreement, Alcon expanded its existing drug research alliance with Origenis GmbH with a focus on the discovery and development of the small molecules that might one day have a role in the treatment of eye diseases. Both agreements were signed by Alcon’s affi liate, Alcon Research, Ltd.

Aureus Pharma licenses AurWEB to Origenis

Paris, FRANCE, September 2006 - Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces that Origenis, a Swiss-German based company who offers creative services in drug design, synthesis and characterization has become the first customer subscribing to its AurWEB portal.

Wall Street Reporter presents Origenis

Munich, Germany, July 2006. Dr. Michael Thormann, Managing Director and Co-Founder, talks about Origenis in an interview with Wall Street Reporter (WSR).

Origenis Extends Research Alliance with Alcon
to Develop Novel Ophthalmic Compounds

Munich, Germany, June, 2006 - Origenis GmbH today announced that it has extended the research alliance with Alcon Research, Ltd. to develop small molecule drugs against important ophthalmic targets for two years. The alliance combines Origenis' compound design and synthesis capabilities with Alcon's applied biology expertise, screening capabilities and development expertise.

Origenis presents at Sportfire Conference

Origenis presents its proprietary multiparametric process for Drug Design, Synthesis and Characterisation at the Sportfire User Conference.

Origenis starts its operations

Origenis starts successfully its operations, after a management buy-out of the former technology group of Morphochem AG